Research
Energy balance
Semaglutide increases the proportion of people achieving 5% weight loss with a risk ratio of 2.68 (95% CI 2.30 to 3.12) at medium-term follow-up.
Semaglutide may significantly help adults with obesity achieve clinically relevant weight loss.
StrongSupportsmedium confidence
semaglutide increases the proportion of people achieving 5% weight loss (risk ratio (RR) 2.68, 95% CI 2.30 to 3.12; 12 studies, 7458 participants; high-certainty evidence).
Why this rating
Based on meta-analysis of randomized controlled trials.
Source
Semaglutide for adults living with obesity
Javier Bracchiglione et al. · Cochrane Database of Systematic Reviews · 2025
Meta-analysisCited 7×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →